Search

Your search keyword '"Tortora, Annalisa"' showing total 249 results
Start Over Author "Tortora, Annalisa"
249 results on '"Tortora, Annalisa"'

2. Development and Validation of a Scoring System to Predict Response to Obeticholic Acid in Primary Biliary Cholangitis

Author

Scaravaglio, Miki, Nofit, Eugenia, Gallo, Paolo, Galati, Giovanni, Pezzato, Francesco, Rollo, Paolo, D’Ovidio, Erica, Coco, Barbara, Tortora, Annalisa, Fiorini, Cecilia, Venere, Rosanna, Scifo, Gaetano, Cannavò, Mariarita, Feletti, Valentina, Pizzolante, Fabrizio, Giannini, Edoardo Giovanni, Cotugno, Rosa, Fanella, Silvia, Losito, Francesco, Grassi, Giuseppe, Manfredi, Giulia Francesca, Buzzanca, Valerio, Omazzi, Barbara, Casella, Silvia, Zani, Francesca, Ricci, Chiara, Bellia, Valentina, Abenavoli, Ludovico, Morelli, Olivia, Crocè, Lory Saveria, Scivetti, Paolo, Panero, Antonio, Boano, Valentina, Poggi, Guido, Gimignani, Giancarlo, Conforti, Alessandro, Frazzetto, Evelise, Rapisarda, Laura, Demma, Shrin, De Vincentis, Antonio, Ampuero, Javier, Terracciani, Francesca, D’Amato, Daphne, Gerussi, Alessio, Cristoferi, Laura, Cazzagon, Nora, Bonaiuto, Emanuela, Floreani, Annarosa, Calvaruso, Vincenza, Cadamuro, Luca, Degasperi, Elisabetta, Morgando, Anna, Vanni, Ester, Lleo, Ana, Colapietro, Francesca, Alvaro, Domenico, Castellaneta, Antonino, Labanca, Sara, Viganò, Mauro, Distefano, Marco, Pace Palitti, Valeria, De Matthaeis, Nicoletta, Marzioni, Marco, Gómez-Dominguez, Elena, Montero, Jose-Luis, Molina, Esther, Garcia-Buey, Luisa, Casado, Marta, Berenguer, Marina, Conde, Isabel, Simon, Miguel-Angel, Fuentes, Javier, Costa-Moreira, Pedro, Macedo, Guilherme, Jorquera, Francisco, Morillas, Rosa-Maria, Presa, Jose, Sousa, Jose-Manuel, Gomes, Dario, Santos, Luis, Olveira, Antonio, Hernandez-Guerra, Manuel, Aburruza, Leire, Santos, Arsenio, Carvalho, Armando, Uriz, Juan, Gutierrez, Maria-Luisa, Perez, Elia, Chessa, Luchino, Pellicelli, Adriano, Marignani, Massimo, Muratori, Luigi, Niro, Grazia Anna, Brunetto, Maurizia, Ponziani, Francesca Romana, Pompili, Maurizio, Marra, Fabio, Galli, Andrea, Mussetto, Alessandro, Alagna, Giuliano, Simone, Loredana, Bertino, Gaetano, Rosina, Floriano, Cozzolongo, Raffaele, Russello, Maurizio, Baiocchi, Leonardo, Saitta, Carlo, Terreni, Natalia, Zolfino, Teresa, Rigamonti, Cristina, Vigano, Raffaella, Cuccorese, Giuseppe, Pozzoni, Pietro, Pedone, Claudio, Grasso, Simone, Picardi, Antonio, Invernizzi, Pietro, Sacco, Rodolfo, Izzi, Antonio, Fernandez-Rodriguez, Conrado, Vespasiani-Gentilucci, Umberto, and Carbone, Marco

Published
2024
Full Text
View/download PDF

3. FRI-078-YI Long-term albumin administration in outpatients with decompensated cirrhosis and diabetes mellitus: post-hoc analysis of the ANSWER trial database

Author

Iannone, Giulia, primary, Zaccherini, Giacomo, additional, Pompili, Enrico, additional, Tedesco, Greta, additional, De Venuto, Clara, additional, Baldassarre, Maurizio, additional, Riggio, Oliviero, additional, Angeli, Paolo, additional, Alessandria, Carlo, additional, Neri, Sergio, additional, Foschi, Francesco, additional, Levantesi, Fabio, additional, Airoldi, Aldo, additional, Simone, Loredana, additional, Svegiati-Baroni, Gianluca, additional, Fagiuoli, Stefano, additional, Laffi, Giacomo, additional, Cozzolongo, Raffaele, additional, Di Marco, Vito, additional, Sangiovanni, Vincenzo, additional, Morisco, Filomena, additional, Toniutto, Pierluigi, additional, Tortora, Annalisa, additional, De Marco, Rosanna, additional, Nardelli, Silvia, additional, Piano, Salvatore, additional, Elia, Chiara, additional, Caraceni, Paolo, additional, and Bernardi, Mauro, additional

Published
2024
Full Text
View/download PDF

6. Lynch Syndrome and Thyroid Nodules: A Single Center Experience.

Author

Spinelli, Irene, Moffa, Simona, Fianchi, Francesca, Mezza, Teresa, Cinti, Francesca, Di Giuseppe, Gianfranco, Marmo, Clelia, Ianiro, Gianluca, Ponziani, Francesca Romana, Tortora, Annalisa, Riccioni, Maria Elena, Giaccari, Andrea, and Gasbarrini, Antonio

Subjects
NEEDLE biopsy, HEREDITARY nonpolyposis colorectal cancer, THYROID nodules, GENETIC disorders, THYROID diseases
Abstract

Background: Lynch syndrome (LS) is a genetic disease with increased risk of colorectal cancer and other malignancies. There are few reported cases of thyroid cancer in LS patients. The aim of this study is to investigate the presence of thyroid nodules in LS patients and to explore their association with the genetic features of the disease. Methods: A retrospective and descriptive analysis was conducted to include all LS patients followed at the CEMAD (Centro Malattie Apparato Digerente) of Fondazione Policlinico Universitario A. Gemelli IRCCS. The characteristics of LS disease, gene mutations, and previous history of thyroid disease were evaluated. Majority of patients underwent thyroid ultrasound (US), and nodule cytology was performed when needed. Results: Of a total of 139 patients with LS, 110 patients were included in the study. A total of 103 patients (74%) underwent thyroid ultrasound examinations, and 7 patients (5%) had a previous history of thyroid disease (cancer or multinodular goiter). The mean age was 51.9 years. Thyroid nodules were found in 62 patients (60%) who underwent US, and 9 of them (14%) had suspicious features of malignancy, inducing a fine-needle aspiration biopsy. A cytologic analysis classified 7 of 9 cases (78%) as TIR2 and 2 (22%) as TIR3a. Between patients with nodular thyroid disease (single nodule, multinodular goiter, and cancer), most of them (25 patients, 36% of total) were carriers of the MSH6 mutation, while 22 (32%), 17 (24%), and 5 (7%) had MSH2, MLH1, and PMS2 mutations, respectively. Conclusions: A high prevalence of thyroid nodules was found in patients with LS, especially in MSH6-carrying patients. Performing at least one thyroid ultrasound examination is suggested for the detection of nodular thyroid disease in LS patients. Systematic investigations are needed to estimate their prevalence, features, and risk of malignant transformation. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. Eosinophilic esophagitis in adults and adolescents: epidemiology, diagnostic challenges, and management strategies for a type 2 inflammatory disease

Author

Savarino, Edoardo Vincenzo, primary, Barbara, Giovanni, additional, Bilò, Maria Beatrice, additional, De Bortoli, Nicola, additional, Di Sabatino, Antonio, additional, Oliva, Salvatore, additional, Penagini, Roberto, additional, Racca, Francesca, additional, Tortora, Annalisa, additional, Rumi, Filippo, additional, and Cicchetti, Americo, additional

Published
2024
Full Text
View/download PDF

8. Long-term real-world experience with obeticholic acid in primary biliary cholangitis: the Italian recapitulate study

Author

Terracciani, Francesca, primary, De Vincentis, Antonio, additional, D’Amato, Daphne, additional, Morgando, Anna, additional, Vanni, Ester, additional, Viganò, Mauro, additional, Alvaro, Domenico, additional, Venere, Rosanna, additional, Lleo, Ana, additional, Colapietro, Francesca, additional, Degasperi, Elisabetta, additional, Viganò, Raffaella, additional, Giannini, Edoardo Giovanni, additional, Labanca, Sara, additional, Feletti, Valentina, additional, Mussetto, Alessandro, additional, Cozzolongo, Raffaele, additional, Losito, Francesco, additional, Pompili, Maurizio, additional, Ponziani, Francesca, additional, Niro, Grazia, additional, Cotugno, Rosa, additional, Pozzoni, Pietro, additional, Chessa, Luchino, additional, Cuccorese, Giuseppe, additional, Palitti, Valeria Pace, additional, Russello, Maurizio, additional, Cannavò, Maria Rita, additional, Frazzetto, Evelise, additional, Bertino, Gaetano, additional, Marzioni, Marco, additional, Terreni, Natalia, additional, Zolfino, Teresa, additional, Saitta, Carlo, additional, Pellicelli, Adriano, additional, Coco, Barbara, additional, Brunetto, Maurizia, additional, Cazzagon, Nora, additional, Floreani, Annarosa, additional, Muratori, Luigi, additional, Rosina, Floriano, additional, Distefano, Marco, additional, Scifo, Gaetano, additional, Baiocchi, Leonardo, additional, Grassi, Giuseppe, additional, Sacco, Rodolfo, additional, Izzi, Antonio, additional, Croce‘, Saveria Lory, additional, Fiorini, Cecilia, additional, Marra, Fabio, additional, Simone, Loredana, additional, Morelli, Olivia, additional, Abenavoli, Ludovico, additional, Pizzolante, Fabrizio, additional, De Matthaeis, Nicoletta, additional, Scaravaglio, Miki, additional, Gimignani, Giancarlo, additional, Boano, Valentina, additional, Francesca, Giulia, additional, Marignani, Massimo, additional, Fanella, Silvia, additional, Giaccetto, Marco, additional, Castellaneta, Antonino, additional, Poggi, Guido, additional, Buzzanca, Valerio, additional, Scivetti, Paolo, additional, Tortora, Annalisa, additional, Casella, Silvia, additional, Bellia, Valentina, additional, Omazzi, Barbara, additional, Alagna, Giuliano, additional, Ricci, Chiara, additional, Poisa, Paolo, additional, Invernizzi, Pietro, additional, Rigamonti, Cristina, additional, Calvaruso, Vincenza, additional, Carbone, Marco, additional, and Gentilucci, Umberto Vespasiani, additional

Published
2023
Full Text
View/download PDF

9. Development and validation of a score predicting response to obeticholic acid in primary biliary cholangitis: the OCA response score (ORS)

Author

De Vincentis, Antonio, primary, Terracciani, Francesca, additional, D’Amato, Daphne, additional, Invernizzi, Pietro, additional, Morgando, Anna, additional, Pellicano, Rinaldo, additional, Vanni, Ester, additional, Viganò, Mauro, additional, Alvaro, Domenico, additional, Venere, Rosanna, additional, Lleo, Ana, additional, Colapietro, Francesca, additional, Degasperi, Elisabetta, additional, Viganò, Raffaella, additional, Giannini, Edoardo Giovanni, additional, Labanca, Sara, additional, Feletti, Valentina, additional, Mussetto, Alessandro, additional, Cozzolongo, Raffaele, additional, Losito, Francesco, additional, Pompili, Maurizio, additional, Ponziani, Francesca, additional, Niro, Grazia, additional, Cotugno, Rosa, additional, Pozzoni, Pietro, additional, Chessa, Luchino, additional, Cuccorese, Giuseppe, additional, Palitti, Valeria Pace, additional, Russello, Maurizio, additional, Cannavò, Maria Rita, additional, Frazzetto, Evelise, additional, Bertino, Gaetano, additional, Marzioni, Marco, additional, Terreni, Natalia, additional, Zolfino, Teresa, additional, Saitta, Carlo, additional, Pellicelli, Adriano, additional, Coco, Barbara, additional, Brunetto, Maurizia, additional, Cazzagon, Nora, additional, Floreani, Annarosa, additional, Muratori, Luigi, additional, Rosina, Floriano, additional, Distefano, Marco, additional, Scifo, Gaetano, additional, Baiocchi, Leonardo, additional, Grassi, Giuseppe, additional, Sacco, Rodolfo, additional, Izzi, Antonio, additional, Croce’, Saveria Lory, additional, Fiorini, Cecilia, additional, Marra, Fabio, additional, Simone, Loredana, additional, Morelli, Olivia, additional, Abenavoli, Ludovico, additional, Pizzolante, Fabrizio, additional, De Matthaeis, Nicoletta, additional, Scaravaglio, Miki, additional, Gimignani, Giancarlo, additional, Boano, Valentina, additional, Francesca, Giulia, additional, Marignani, Massimo, additional, Fanella, Silvia, additional, Giaccetto, Marco, additional, Castellaneta, Antonino, additional, Poggi, Guido, additional, Buzzanca, Valerio, additional, Scivetti, Paolo, additional, Tortora, Annalisa, additional, Casella, Silvia, additional, Bellia, Valentina, additional, Omazzi, Barbara, additional, Alagna, Giuliano, additional, Ricci, Chiara, additional, Poisa, Paolo, additional, Rigamonti, Cristina, additional, Calvaruso, Vincenza, additional, Gentilucci, Umberto Vespasiani, additional, and Carbone, Marco, additional

Published
2023
Full Text
View/download PDF

11. Correction and prevention of hyponatremia in patients with cirrhosis and ascites-post hoc analysis of the ANSWER study database

Author

Zaccherini, Giacomo, primary, Baldassarre, Maurizio, additional, Tufoni, Manuel, additional, Riggio, Oliviero, additional, Angeli, Paolo, additional, Alessandria, Carlo, additional, Neri, Sergio, additional, Foschi, Francesco Giuseppe, additional, Levantesi, Fabio, additional, Airoldi, Aldo, additional, Simone, Loredana, additional, Svegiati-Baroni, Gianluca, additional, Fagiuoli, Stefano, additional, Laffi, Giacomo, additional, Cozzolongo, Raffaele, additional, Di Marco, Vito, additional, Sangiovanni, Vincenzo, additional, Morisco, Filomena, additional, Toniutto, Pierluigi, additional, Tortora, Annalisa, additional, De Marco, Rosanna, additional, Nardelli, Silvia, additional, Piano, Salvatore, additional, Elia, Chiara, additional, Bernardi, Mauro, additional, and Caraceni, Paolo, additional

Published
2022
Full Text
View/download PDF

12. Risk for Surgery in Patients with Polyposis Syndrome after Therapy by Device-Assisted Enteroscopy (DAE): Long-Term Follow Up

Author

Marmo, Clelia, Tortora, Annalisa, Costamagna, Guido, Nicolò, Rebecca, Riccioni, Maria Elena, Clelia Marmo, Annalisa Tortora, Guido Costamagna (ORCID:0000-0002-8100-2731), Rebecca Nicolò, Maria Elena Riccioni (ORCID:0000-0002-9239-4312), Marmo, Clelia, Tortora, Annalisa, Costamagna, Guido, Nicolò, Rebecca, Riccioni, Maria Elena, Clelia Marmo, Annalisa Tortora, Guido Costamagna (ORCID:0000-0002-8100-2731), Rebecca Nicolò, and Maria Elena Riccioni (ORCID:0000-0002-9239-4312)

Abstract

Background and aim of the study: Polyposis syndromes such as Peutz–Jeghers (PJ) and familial adenomatous polyposis (FAP) are associated with the growth of small bowel polyps; the risk is approximately 60–90% for PJ and 40–70% for FAP. The primary aim of this study was to evaluate the efficacy of device-assisted enteroscopy (DAE) in the detection and treatment of small bowel polyps to reduce the risk of surgery. The secondary objective was to study complications and mortality. Methods: We conducted a retrospective cohort study by analyzing a structured database. Between September 2006 and October 2019, we observed and followed 42 consecutive patients with polyposis syndromes; they underwent device-assisted enteroscopy and three were excluded from elective surgery after the exam. The endoscopic exams were performed for diagnostic and therapeutic purposes. Results: Thirty-nine patients were evaluated with a mean follow up of 6.7 years (±SD 2.7), 79.5% were female with a mean age of 43.8 years (±SD 15.02), and 68 enteroscopies were performed with the removal of 64 polypoid lesions. One bleeding episode occurred after operative enteroscopy, and the need for subsequent surgery occurred in six patients with PJ and in five patients with FAP. The surgical indications in PJ patients were the presence of large polyps (three patients) and three cases of intussusception, one of which was a patient with a polyp in the proximal ileum, not reachable with the scope. One patient with PJ died from pancreatic cancer during follow up. The surgical indications in patients with FAP were the presence of four large polyps with high-grade dysplasia and one ampullary neoplasia recurrence. Conclusions: In PJ patients, the endoscopic treatment of small bowel polyps was safe. During the follow-up period, the patients with successful endoscopic treatment did not need surgery. In FAP patients treated with DAE, none developed cancer.

Published
2022

13. IDegLira for the Real-World Treatment of Type 2 Diabetes in Italy: Protocol and Interim Results from the REX Observational Study

Author

Fadini, G. P., Buzzetti, R., Fittipaldi, M. R., D'Incau, F., Da Porto, A., Girelli, A., Simoni, L., Lastoria, G., Consoli, A., Iazzetta, N., Di Giovanni, G., Carbonara, O., Aragiusto, C., Carleo, D., Da Rosa, N., Martedi, E., Landolfi, L., Marracino, M., Tortora, Annalisa, De Morelli, G., Casarsa, V., Maddaloni, E., Siena, Annunziata, Pitocco, Dario, Tartaglione, Linda, Rizzi, A., Leonetti, F., Fasolo, M., Morsello, G., Bulzomi, R., Ruga, G., Bianconi, A., Torre, Enza, Rebora, A., Cecoli, F., Monti, E., Bonfadini, S., Dotti, S., Madaschi, S., Trevisan, R., Albizzi, M., Bellante, R., Corsi, Alessandro, Scaranna, C., De Cata, P., Liboa, F., Ghilotti, S., Tortato, E., Lanari, L., Turchi, F., Gabellieri, E., Lamacchia, O., Colucci, C., Mileti, G., Coluzzi, Simone, Carrieri, F., Rossetti, P., Anzaldi, Mauro, Di Benedetto, A., Ruggeri, D., Scatena, A., Ranchelli, A., Ragusa, I., Gregori, G., Crisci, I., Mori, Marco Ernesto, Baccetti, F., Anichini, R., Salutini, E., Vinci, C., Colletti, I., Zanon, M. S., Altomari, A., Bonora, B. M., Tortora A., Siena A., Pitocco D. (ORCID:0000-0002-6220-686X), Tartaglione L., Torre E. (ORCID:0000-0001-6754-2611), Corsi A., Coluzzi S., Anzaldi M. (ORCID:0009-0006-0614-2060), Mori M., Fadini, G. P., Buzzetti, R., Fittipaldi, M. R., D'Incau, F., Da Porto, A., Girelli, A., Simoni, L., Lastoria, G., Consoli, A., Iazzetta, N., Di Giovanni, G., Carbonara, O., Aragiusto, C., Carleo, D., Da Rosa, N., Martedi, E., Landolfi, L., Marracino, M., Tortora, Annalisa, De Morelli, G., Casarsa, V., Maddaloni, E., Siena, Annunziata, Pitocco, Dario, Tartaglione, Linda, Rizzi, A., Leonetti, F., Fasolo, M., Morsello, G., Bulzomi, R., Ruga, G., Bianconi, A., Torre, Enza, Rebora, A., Cecoli, F., Monti, E., Bonfadini, S., Dotti, S., Madaschi, S., Trevisan, R., Albizzi, M., Bellante, R., Corsi, Alessandro, Scaranna, C., De Cata, P., Liboa, F., Ghilotti, S., Tortato, E., Lanari, L., Turchi, F., Gabellieri, E., Lamacchia, O., Colucci, C., Mileti, G., Coluzzi, Simone, Carrieri, F., Rossetti, P., Anzaldi, Mauro, Di Benedetto, A., Ruggeri, D., Scatena, A., Ranchelli, A., Ragusa, I., Gregori, G., Crisci, I., Mori, Marco Ernesto, Baccetti, F., Anichini, R., Salutini, E., Vinci, C., Colletti, I., Zanon, M. S., Altomari, A., Bonora, B. M., Tortora A., Siena A., Pitocco D. (ORCID:0000-0002-6220-686X), Tartaglione L., Torre E. (ORCID:0000-0001-6754-2611), Corsi A., Coluzzi S., Anzaldi M. (ORCID:0009-0006-0614-2060), and Mori M.

Abstract

Introduction: IDegLira was shown to maintain glycemic control while reducing risk of hypoglycemia and body weight gain. The REX study was designed to generate real-world evidence on the use of IDegLira in Italian clinical practice in two different subgroups of patients, those switching to IDegLira from a basal insulin-supported oral therapy (BOT group) and those from a basal plus bolus insulin regimen (BB group). Methods: Adult patients with T2D diagnosed for at least 12 months and having started IDegLira 2–3 months prior to enrolment, coming from a BOT or BB regimen, were enrolled in this multicenter observational prospective cohort study conducted in 28 Italian centers. This paper presents the methodological framework of the REX study and provides the interim analysis results describing the patients’ baseline characteristics and the clinical reasons for IDegLira treatment initiation. Results: Of the 360 patients enrolled in the REX study, 331 were considered eligible for this interim analysis, 76.4% in the BOT and 23.6% in the BB group. Mean (SD) HbA1c was 8.5% (1.4) in the BOT and 8.2% (1.7) in the BB group. The most common T2D complications were diabetic macroangiopathy and diabetic nephropathy in both groups. The median (interquartile range) insulin daily dose before IDegLira was 15.0 (10.0–20.0) units in the BOT group and 42 (30.0–52.0) in the BB group. Oral antidiabetics were taken by 98% and 51.3% of patients, respectively. The main reason for switching to IDegLira was the inadequate glycemic control in the BOT group (86% of patients), and the intent to simplify the treatment in the BB group (66.7%). Conclusions: IdegLira is initiated after BOT in inadequately controlled patients to improve glycemic control, whereas in BB patients it is used to simplify the therapeutic regimen. Final results of the REX study will shed light on patients’ outcomes after IdegLira treatment under routine clinical care.

Published
2022

14. Correction and prevention of hyponatremia in patients with cirrhosis and ascites-post hoc analysis of the ANSWER study database

Author

Giacomo Zaccherini, Baldassarre, Maurizio, Tufoni, Manuel, Riggio, Oliviero, Angeli, Paolo, Alessandria, Carlo, Neri, Sergio, Foschi, Francesco Giuseppe, Levantesi, Fabio, Airoldi, Aldo, Simone, Loredana, Svegiati-Baroni, Gianluca, Fagiuoli, Stefano, Laffi, Giacomo, Cozzolongo, Raffaele, Di Marco, Vito, Sangiovanni, Vincenzo, Morisco, Filomena, Toniutto, Pierluigi, Tortora, Annalisa, Marco, Rosanna, Nardelli, Silvia, Piano, Salvatore, Elia, Chiara, Bernardi, Mauro, and Caraceni, Paolo

Subjects
Hepatology
Published
2022

17. Feasibility and diagnostic yield of small-bowel capsule endoscopy in patients with surgically altered gastric anatomy: the SAGA study

Author

Dray, Xavier, primary, Riccioni, Maria Elena, additional, Wurm Johansson, Gabriele, additional, Keuchel, Martin, additional, Perrod, Guillaume, additional, Martin, Antoine, additional, Tortora, Annalisa, additional, Nemeth, Artur, additional, Baltes, Peter, additional, Pérez-Cuadrado-Robles, Enrique, additional, Chetcuti Zammit, Stefania, additional, Lee, Phey Shen, additional, Leenhardt, Romain, additional, Koulaouzidis, Anastasios, additional, Dray, Xavier, additional, Cadoni, Sergio, additional, Fernández-Urien Sainz, Ignacio, additional, McNamara, Deirdre, additional, Margalit-Yehuda, Reuma, additional, Beaumont, Hanneke, additional, Mussetto, Alessandro, additional, Spada, Cristiano, additional, Elli, Luca, additional, Triantafyllou, Konstantinos, additional, Ellul, Pierre, additional, Bruno, Mauro, additional, Rondonotti, Emanuele, additional, Robertson, Alexander, additional, and Cortegoso Valdivia, Pablo, additional

Published
2021
Full Text
View/download PDF

19. ID: 3519521 FEASIBILITY AND DIAGNOSTIC YIELD OF SMALL BOWEL CAPSULE ENDOSCOPY IN PATIENTS WITH SURGICALLY ALTERED GASTRIC ANATOMY

Author

Dray, Xavier, primary, Riccioni, Maria Elena, additional, Johansson, Gabriele W., additional, Keuchel, Martin, additional, Perrod, Guillaume, additional, Martin, Antoine, additional, Tortora, Annalisa, additional, Nemeth, Artur, additional, Baltes, Peter, additional, Cuadrado Robles, Enrique Perez, additional, Zammit, Stefania Chetcuti, additional, Lee, Phey Shen, additional, Cadoni, Sergio, additional, Fernandez-Urien, Ignacio, additional, Mcnamara, Deirdre, additional, Margalit-Yehuda, Reuma, additional, Beaumont, Hanneke, additional, Mussetto, Alessandro, additional, Spada, Cristiano, additional, Elli, Luca, additional, Triantafyllou, Konstantinos, additional, Ellul, Pierre, additional, Bruno, Mauro, additional, Rondonotti, Emanuele, additional, Robertson, Alexander, additional, Leenhardt, Romain, additional, and Koulaouzidis, Anastasios, additional

Published
2021
Full Text
View/download PDF

20. Feasibility and diagnostic yield of small-bowel capsule endoscopy in patients with surgically altered gastric anatomy: the SAGA study

Author

Dray, X., Riccioni, Maria Elena, Wurm Johansson, G., Keuchel, M., Perrod, G., Martin, A., Tortora, Annalisa, Nemeth, A., Baltes, P., Perez-Cuadrado-Robles, E., Chetcuti Zammit, S., Lee, P. S., Leenhardt, R., Koulaouzidis, A., Cadoni, S., Fernandez-Urien Sainz, I., Mcnamara, D., Margalit-Yehuda, R., Beaumont, H., Mussetto, A., Spada, Cristiano, Elli, L., Triantafyllou, K., Ellul, P., Bruno, M., Rondonotti, E., Robertson, A., Cortegoso Valdivia, P., Riccioni M. E. (ORCID:0000-0002-9239-4312), Tortora A., Spada C. (ORCID:0000-0002-5692-0960), Dray, X., Riccioni, Maria Elena, Wurm Johansson, G., Keuchel, M., Perrod, G., Martin, A., Tortora, Annalisa, Nemeth, A., Baltes, P., Perez-Cuadrado-Robles, E., Chetcuti Zammit, S., Lee, P. S., Leenhardt, R., Koulaouzidis, A., Cadoni, S., Fernandez-Urien Sainz, I., Mcnamara, D., Margalit-Yehuda, R., Beaumont, H., Mussetto, A., Spada, Cristiano, Elli, L., Triantafyllou, K., Ellul, P., Bruno, M., Rondonotti, E., Robertson, A., Cortegoso Valdivia, P., Riccioni M. E. (ORCID:0000-0002-9239-4312), Tortora A., and Spada C. (ORCID:0000-0002-5692-0960)

Abstract

Background and Aims: Little is known about small-bowel (SB) capsule endoscopy (CE) in patients with a history of gastric surgery. This study aims to evaluate the feasibility and diagnostic yield (DY) of orally ingested SB-CE in patients with surgically altered gastric anatomy. Methods: Twenty-four European centers retrospectively identified patients who had SB-CE after total or subtotal gastrectomy. The primary outcome was the DY of SB-CE (intermediate P1 to highly P2 relevant findings). Secondary outcomes were gastric and SB transit times, completion, cleanliness, and adverse event rates. Results: Studied were 248 procedures from 243 patients (mean age, 62 years) with a history of partial gastrectomy (Billroth I, 13.1%; Billroth II, 34.6%), total gastrectomy (7.4%), Whipple procedure (12.8%), sleeve gastrectomy (7.2%), or gastric bypass surgery (24.7%). Obscure GI bleeding was the most frequent indication (85.1%). SB completion rate was 84.3%. One capsule retention in the SB was noted (adverse event rate, 4%). Median SB transit time was 286 minutes (interquartile range [235; 387]). Cleanliness was rated as adequate in 92.1% of procedures. After exclusion of abnormalities found at the upper anastomotic site, the DY was 43.6%, with inflammatory/ulcerated lesions observed more frequently (23.4%) than vascular lesions (21.0%). Conclusions: SB-CE seems to be feasible and safe in selected patients with a history of major gastric surgery and comes with a high DY. The spectrum of abnormal SB findings in these patients may be different from what is known from the literature in nonoperated patients.

Published
2021

21. Feasibility and diagnostic yield of small-bowel capsule endoscopy in patients with surgically altered gastric anatomy: the SAGA study

Author

Dray, Xavier, Riccioni, Maria Elena, Wurm Johansson, Gabriele, Keuchel, Martin, Perrod, Guillaume, Martin, Antoine, Tortora, Annalisa, Nemeth, Artur, Baltes, Peter, Pérez-Cuadrado-Robles, Enrique, Chetcuti Zammit, Stefania, Shen Lee, Phey, Leenhardt, Romain, Koulaouzidis, Anastasio, CARE Group, I, Maria Elena Riccioni (ORCID:0000-0002-9239-4312), Annalisa Tortora, Dray, Xavier, Riccioni, Maria Elena, Wurm Johansson, Gabriele, Keuchel, Martin, Perrod, Guillaume, Martin, Antoine, Tortora, Annalisa, Nemeth, Artur, Baltes, Peter, Pérez-Cuadrado-Robles, Enrique, Chetcuti Zammit, Stefania, Shen Lee, Phey, Leenhardt, Romain, Koulaouzidis, Anastasio, CARE Group, I, Maria Elena Riccioni (ORCID:0000-0002-9239-4312), and Annalisa Tortora

Abstract

Background and aims: Little is known about small-bowel (SB) capsule endoscopy (CE) in patients with a history of gastric surgery. This study aims to evaluate the feasibility and diagnostic yield (DY) of orally ingested SB-CE in patients with surgically altered gastric anatomy. Methods: Twenty-four European centers retrospectively identified patients who had SB-CE after total or subtotal gastrectomy. The primary outcome was the DY of SB-CE (intermediate P1 to highly P2 relevant findings). Secondary outcomes were gastric and SB transit times, completion, cleanliness, and adverse event rates. Results: Studied were 248 procedures from 243 patients (mean age, 62 years) with a history of partial gastrectomy (Billroth I, 13.1%; Billroth II, 34.6%), total gastrectomy (7.4%), Whipple procedure (12.8%), sleeve gastrectomy (7.2%), or gastric bypass surgery (24.7%). Obscure GI bleeding was the most frequent indication (85.1%). SB completion rate was 84.3%. One capsule retention in the SB was noted (adverse event rate, .4%). Median SB transit time was 286 minutes (interquartile range [235; 387]). Cleanliness was rated as adequate in 92.1% of procedures. After exclusion of abnormalities found at the upper anastomotic site, the DY was 43.6%, with inflammatory/ulcerated lesions observed more frequently (23.4%) than vascular lesions (21.0%). Conclusions: SB-CE seems to be feasible and safe in selected patients with a history of major gastric surgery and comes with a high DY. The spectrum of abnormal SB findings in these patients may be different from what is known from the literature in nonoperated patients.

Published
2021

22. Missed linkage to care for patients who screened positive for Hepatitis C in a tertiary care centre: Results of the Telepass project

Author

Ponziani, Francesca Romana, Santopaolo, Francesco, Siciliano, Massimo, De Belvis, A. G., Tortora, Annalisa, Mora, Vincenzina, Fanali, Chiara, Morsella, Alisha, Balducci, Federica, Vetrugno, Giuseppe, D'Alfonso, Maria Elena, Cambieri, Andrea, Cauda, Roberto, Bellantone, Rocco Domenico Alfonso, Sanguinetti, Maurizio, Pompili, Maurizio, Gasbarrini, Antonio, Ponziani F. R. (ORCID:0000-0002-5924-6238), Santopaolo F., Siciliano M., Tortora A., Mora V., Fanali C., Morsella A., Balducci F., Vetrugno G. (ORCID:0000-0003-0181-2855), D'Alfonso M. E., Cambieri A., Cauda R. (ORCID:0000-0002-1498-4229), Bellantone R. (ORCID:0000-0002-0844-3469), Sanguinetti M. (ORCID:0000-0002-9780-7059), Pompili M. (ORCID:0000-0001-6699-7980), Gasbarrini A. (ORCID:0000-0002-7278-4823), Ponziani, Francesca Romana, Santopaolo, Francesco, Siciliano, Massimo, De Belvis, A. G., Tortora, Annalisa, Mora, Vincenzina, Fanali, Chiara, Morsella, Alisha, Balducci, Federica, Vetrugno, Giuseppe, D'Alfonso, Maria Elena, Cambieri, Andrea, Cauda, Roberto, Bellantone, Rocco Domenico Alfonso, Sanguinetti, Maurizio, Pompili, Maurizio, Gasbarrini, Antonio, Ponziani F. R. (ORCID:0000-0002-5924-6238), Santopaolo F., Siciliano M., Tortora A., Mora V., Fanali C., Morsella A., Balducci F., Vetrugno G. (ORCID:0000-0003-0181-2855), D'Alfonso M. E., Cambieri A., Cauda R. (ORCID:0000-0002-1498-4229), Bellantone R. (ORCID:0000-0002-0844-3469), Sanguinetti M. (ORCID:0000-0002-9780-7059), Pompili M. (ORCID:0000-0001-6699-7980), and Gasbarrini A. (ORCID:0000-0002-7278-4823)

Abstract

Italy is one of the countries on track with the WHO’s agenda to eliminate hepatitis C virus (HCV) by 2030. Healthcare facilities play a crucial role in seeking patients who are infected but have not yet been treated. We assessed the effectiveness of a recall strategy, named ‘Telepass’ project, for patients exposed to HCV infection who have not yet been linked to care in a large tertiary care centre. The ‘Telepass’ project was structured in two phases: (a) a retrospective analysis first identified all anti–HCV-positive subjects among patients who underwent pre-operative assessment in the facility in the course of one year; (b) a following prospective phase, aimed to recall patients in need either of further diagnostic tests (ie HCV-RNA) or treatment. A total of 12246 records of patients tested for HCV antibodies were reviewed. The overall prevalence of anti–HCV-positive subjects was 1.83% (224/12246) with a male/female ratio of 2.07. Out of the 224 anti–HCV-positive patients, 123 (54.91%) did not have documented HCV-RNA tests and were therefore selected for recall. Of these, 123 were reachable and 26 (21.13%) were successfully linked to care. Ten patients (38.46%) tested HCV-RNA positive and initiated treatment with direct-acting antivirals (DAAs). The Telepass study highlights that a recall strategy starting from internal hospital databases can help identify patients with chronic HCV infection who have not yet been linked to care, and provides an epidemiological insight into the prevalence of HCV infection in Italy in the late DAAs era.

Published
2021

26. OS-070 - Development and validation of a score predicting response to obeticholic acid in primary biliary cholangitis: the OCA response score (ORS)

Author

De Vincentis, Antonio, Terracciani, Francesca, D’Amato, Daphne, Invernizzi, Pietro, Morgando, Anna, Pellicano, Rinaldo, Vanni, Ester, Viganò, Mauro, Alvaro, Domenico, Venere, Rosanna, Lleo, Ana, Colapietro, Francesca, Degasperi, Elisabetta, Viganò, Raffaella, Giannini, Edoardo Giovanni, Labanca, Sara, Feletti, Valentina, Mussetto, Alessandro, Cozzolongo, Raffaele, Losito, Francesco, Pompili, Maurizio, Ponziani, Francesca, Niro, Grazia, Cotugno, Rosa, Pozzoni, Pietro, Chessa, Luchino, Cuccorese, Giuseppe, Palitti, Valeria Pace, Russello, Maurizio, Cannavò, Maria Rita, Frazzetto, Evelise, Bertino, Gaetano, Marzioni, Marco, Terreni, Natalia, Zolfino, Teresa, Saitta, Carlo, Pellicelli, Adriano, Coco, Barbara, Brunetto, Maurizia, Cazzagon, Nora, Floreani, Annarosa, Muratori, Luigi, Rosina, Floriano, Distefano, Marco, Scifo, Gaetano, Baiocchi, Leonardo, Grassi, Giuseppe, Sacco, Rodolfo, Izzi, Antonio, Croce’, Saveria Lory, Fiorini, Cecilia, Marra, Fabio, Simone, Loredana, Morelli, Olivia, Abenavoli, Ludovico, Pizzolante, Fabrizio, De Matthaeis, Nicoletta, Scaravaglio, Miki, Gimignani, Giancarlo, Boano, Valentina, Francesca, Giulia, Marignani, Massimo, Fanella, Silvia, Giaccetto, Marco, Castellaneta, Antonino, Poggi, Guido, Buzzanca, Valerio, Scivetti, Paolo, Tortora, Annalisa, Casella, Silvia, Bellia, Valentina, Omazzi, Barbara, Alagna, Giuliano, Ricci, Chiara, Poisa, Paolo, Rigamonti, Cristina, Calvaruso, Vincenza, Gentilucci, Umberto Vespasiani, and Carbone, Marco

Published
2023
Full Text
View/download PDF

27. OS-045 - Long-term real-world experience with obeticholic acid in primary biliary cholangitis: the Italian recapitulate study

Author

Terracciani, Francesca, De Vincentis, Antonio, D’Amato, Daphne, Morgando, Anna, Vanni, Ester, Viganò, Mauro, Alvaro, Domenico, Venere, Rosanna, Lleo, Ana, Colapietro, Francesca, Degasperi, Elisabetta, Viganò, Raffaella, Giannini, Edoardo Giovanni, Labanca, Sara, Feletti, Valentina, Mussetto, Alessandro, Cozzolongo, Raffaele, Losito, Francesco, Pompili, Maurizio, Ponziani, Francesca, Niro, Grazia, Cotugno, Rosa, Pozzoni, Pietro, Chessa, Luchino, Cuccorese, Giuseppe, Palitti, Valeria Pace, Russello, Maurizio, Cannavò, Maria Rita, Frazzetto, Evelise, Bertino, Gaetano, Marzioni, Marco, Terreni, Natalia, Zolfino, Teresa, Saitta, Carlo, Pellicelli, Adriano, Coco, Barbara, Brunetto, Maurizia, Cazzagon, Nora, Floreani, Annarosa, Muratori, Luigi, Rosina, Floriano, Distefano, Marco, Scifo, Gaetano, Baiocchi, Leonardo, Grassi, Giuseppe, Sacco, Rodolfo, Izzi, Antonio, Croce‘, Saveria Lory, Fiorini, Cecilia, Marra, Fabio, Simone, Loredana, Morelli, Olivia, Abenavoli, Ludovico, Pizzolante, Fabrizio, De Matthaeis, Nicoletta, Scaravaglio, Miki, Gimignani, Giancarlo, Boano, Valentina, Francesca, Giulia, Marignani, Massimo, Fanella, Silvia, Giaccetto, Marco, Castellaneta, Antonino, Poggi, Guido, Buzzanca, Valerio, Scivetti, Paolo, Tortora, Annalisa, Casella, Silvia, Bellia, Valentina, Omazzi, Barbara, Alagna, Giuliano, Ricci, Chiara, Poisa, Paolo, Invernizzi, Pietro, Rigamonti, Cristina, Calvaruso, Vincenza, Carbone, Marco, and Gentilucci, Umberto Vespasiani

Published
2023
Full Text
View/download PDF

28. Management of gastrointestinal bleeding in rendu-osler disease

Author

Tortora, Annalisa, Marmo, Clelia, Gasbarrini, Antonio, Costamagna, Guido, Riccioni, Maria Elena, Tortora A., Marmo C., Gasbarrini A. (ORCID:0000-0002-7278-4823), Costamagna G. (ORCID:0000-0002-8100-2731), Riccioni M. E. (ORCID:0000-0002-9239-4312), Tortora, Annalisa, Marmo, Clelia, Gasbarrini, Antonio, Costamagna, Guido, Riccioni, Maria Elena, Tortora A., Marmo C., Gasbarrini A. (ORCID:0000-0002-7278-4823), Costamagna G. (ORCID:0000-0002-8100-2731), and Riccioni M. E. (ORCID:0000-0002-9239-4312)

Abstract

Background: Hereditary hemorrhagic telangiectasia (HHT, or Rendu-Osler-Weber dis-ease) is a rare inherited syndrome, characterized by artero-venous malformations (AVMs or te-langiectasia) with autosomal dominant transmission. AVMs can occur in any organ of the body but most commonly it occurs in the nose, pulmonary, hepatic and cerebral circulations. In patients with HHT, we report teleangectasia of mucosa of the gastrointestinal tract. Methods: Research and online content related to HHT online activity is reviewed, and DOC writ-ing excerpts are used to illustrate key themes. Results: Patients with HHT have a high rate of complications related to bleeding; of them gastrointestinal bleeding accounts for 10.8%. Several therapies, both medical and endoscopic, were utilized to reduce the need for transfusions and hospitalization. Conclusion: A combination of medical and endoscopic therapy is probably the best option.

Published
2020

29. Gastrointestinal Manifestations in Hereditary Transthyretin Amyloidosis: a Single-Centre Experience

Author

Luigetti, Marco, Tortora, Annalisa, Romano, Angela, Di Paolantonio, Andrea, Guglielmino, Valeria, Bisogni, Giulia, Gasbarrini, Antonio, Calabresi, Paolo, Sabatelli, Mario, Luigetti, Marco (ORCID:0000-0001-7539-505X), Gasbarrini, Antonio (ORCID:0000-0002-7278-4823), Calabresi, Paolo (ORCID:0000-0003-0326-5509), Sabatelli, Mario (ORCID:0000-0001-6635-4985), Luigetti, Marco, Tortora, Annalisa, Romano, Angela, Di Paolantonio, Andrea, Guglielmino, Valeria, Bisogni, Giulia, Gasbarrini, Antonio, Calabresi, Paolo, Sabatelli, Mario, Luigetti, Marco (ORCID:0000-0001-7539-505X), Gasbarrini, Antonio (ORCID:0000-0002-7278-4823), Calabresi, Paolo (ORCID:0000-0003-0326-5509), and Sabatelli, Mario (ORCID:0000-0001-6635-4985)

Abstract

Background and Aims: Hereditary transthyretin (ATTRv) amyloidosis represents a diagnostic challenge considering the great variability in clinical presentation and multiorgan involvement. In this study we report the prevalence of gastrointestinal (GI) involvement of patients with hereditary ATTRv amyloidosis from one single center of Italy, a non-endemic area. Methods: We retrospectively analyzed a cohort of 39 patients with hereditary ATTRv amyloidosis followed at the Neurology Unit of Fondazione Policlinico Universitario A. Gemelli IRCCS in Rome, Italy. All patients had a documented mutation in the gene encoding the thansthyretin. Neurological, cardiological and gastrointestinal manifestations were systematically collected at every monitoring visit. Results: 82% reported at least one GI symptom. Unintentional weight loss was the most frequently reported. Lower GI symptoms were more frequent than upper GI symptoms (66.7% vs. 35.9%, p=0.0122). The first GI symptom was always reported within 5 years since disease onset. Gastrointestinal symptoms were almost always present in patients with Val30Met mutation (93.8%, 15/16), and in more than half of the cases with Phe64Leu mutation (66.7%, 8/12). All cases with a non-Val30Met mutation disclosed almost all GI symptoms within 5 years since disease onset; conversely, patients with Val30Met mutation continued to develop further GI manifestations during the disease course. Conclusions: Prevalence of GI symptoms in our cohort was 82%, resulting in a higher prevalence than reported in the THAOS registry. Gastroenterologists, therefore, play an important role for the management of the disease, and their expertise should be valued for an effective multidisciplinary approach to this condition.

Published
2020

30. Safety of antithrombotic therapy in subjects with hereditary hemorrhagic telangiectasia: prospective data from a multidisciplinary working group

Author

Gaetani, Eleonora, Agostini, Fabiana, Porfidia, Angelo, Giarretta, Igor, Feliciani, Daniela, Di Martino, Luigi, Tortora, Annalisa, Gasbarrini, Antonio, Pola, Roberto, Passali, Giulio Cesare, Riccioni, Maria Elena, Puca, Alfredo, Sturiale, Carmelo Lucio, Riccardi, L, Di Stasi, Carmine, Contegiacomo, Andrea, Del Ciello AE, Ferraro, Pietro Manuel, Cavaliere, Af, Lucci Cordisco, Emanuela, Zampino, Giuseppe, Giorgio, Valentina, Ojetti, Veronica, Marrone, G, Spoletini, G, Locorotondo, G, Lanza, Gaetano Antonio, De Candia, Erica, Peppucci, Elisabetta, Corina, Luigi, and Lombardi, Mt.

Subjects
Male, 0301 basic medicine, Pediatrics, medicine.medical_specialty, Blood transfusion, medicine.medical_treatment, Interdisciplinary Research, Settore MED/27 - NEUROCHIRURGIA, lcsh:Medicine, antithrombotic therapy, 030105 genetics & heredity, Hemoglobins, 03 medical and health sciences, 0302 clinical medicine, Fibrinolytic Agents, Antithrombotic, medicine, Humans, Pharmacology (medical), Prospective Studies, Prospective cohort study, Telangiectasia, Letter to the Editor, Genetics (clinical), Aged, Hereditary Hemorrhagic Teleangectasia, antithrombotic therapy, business.industry, lcsh:R, Settore MED/09 - MEDICINA INTERNA, Autosomal dominant trait, General Medicine, Middle Aged, Hereditary Hemorrhagic Teleangectasia, Interim analysis, medicine.disease, Thrombosis, Discontinuation, Female, Telangiectasia, Hereditary Hemorrhagic, Settore MED/31 - OTORINOLARINGOIATRIA, medicine.symptom, business, 030217 neurology & neurosurgery
Abstract

Subjects with the rare autosomal dominant disease Hereditary Hemorrhagic Telangiectasia (HHT) may develop medical conditions that require antithrombotic therapy (AT). However, safety of AT is uncertain in these patients and the only data currently available derive from retrospective analyses of registries and/or databases. At the HHT Centre of the ‘Fondazione Policlinico Universitario A. Gemelli IRCCS’ (Rome, Italy), a prospective study is currently ongoing to evaluate the safety of AT in subjects affected by HHT. The study is enrolling subjects with a definite diagnosis of HHT who receive an AT prescription by one of the physicians of the HHT Centre. The primary outcome is the number of hemorrhagic events, distinguished in major, clinically relevant non-major (CRNM), and minor bleedings, according to the criteria of the International Society on Thrombosis and Hemostasis (ISTH). Another primary outcome is worsening of epistaxis upon initiation of AT, assessed using the internationally accepted Epistaxis Severity Score (ESS). Additional outcomes are changes in hemoglobin levels and changes in the need of blood transfusion after initiation of AT. Here, we present the results of an interim analysis, conducted on the 12 HHT subjects that have been enrolled so far. After a mean follow-up of 6.5 ± 0.8 months, no major bleedings, no CRNM bleedings, and no minor bleedings different from epistaxis were recorded. Worsening of epistaxis upon initiation of AT was documented only in one patient, but did not require discontinuation of AT. There were no significant changes in the mean ESS measured before and after initiation of AT. There were no significant changes in hemoglobin levels and need for blood transfusion after initiation of AT. Although preliminary, these are the first prospective data on the safety of AT in HHT patients. Our interim analysis suggests that, when prescribed by experienced physicians in a multidisciplinary setting, AT is well tolerated by HHT patients. More patients and a longer follow-up are needed to confirm these findings.

Published
2019

32. On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites

Author

Caraceni, Paolo, primary, Tufoni, Manuel, additional, Zaccherini, Giacomo, additional, Riggio, Oliviero, additional, Angeli, Paolo, additional, Alessandria, Carlo, additional, Neri, Sergio, additional, Foschi, Francesco G., additional, Levantesi, Fabio, additional, Airoldi, Aldo, additional, Simone, Loredana, additional, Svegliati-Baroni, Gianluca, additional, Fagiuoli, Stefano, additional, Laffi, Giacomo, additional, Cozzolongo, Raffaele, additional, Di Marco, Vito, additional, Sangiovanni, Vincenzo, additional, Morisco, Filomena, additional, Toniutto, Pierluigi, additional, Gasbarrini, Antonio, additional, De Marco, Rosanna, additional, Piano, Salvatore, additional, Nardelli, Silvia, additional, Elia, Chiara, additional, Roncadori, Andrea, additional, Baldassarre, Maurizio, additional, Bernardi, Mauro, additional, Domenicali, Marco, additional, Giannone, Ferdinando A., additional, Antognoli, Agnese, additional, Merli, Manuela, additional, Pasquale, Chiara, additional, Gioia, Stefania, additional, Fasolato, Silvano, additional, Sticca, Antonietta, additional, Campion, Daniela, additional, Risso, Alessandro, additional, Saracco, Giorgio M., additional, Prestianni, Loredana, additional, Fidone, Federica, additional, Maiorca, Daniela, additional, Rizzotto, Agostino, additional, Cappa, Federica Mirici, additional, Lanzi, Arianna, additional, Neri, Elga, additional, Visani, Anna, additional, Mastroianni, Antonio, additional, Perricone, Giovanni, additional, Alberti, Alberto B., additional, Cesarini, Lucia, additional, Mazzarelli, Chiara, additional, Vangeli, Marcello, additional, Viganò, Raffaella, additional, Marzioni, Marco, additional, Capretti, Francesca, additional, Kostandini, Alba, additional, Magini, Giulia, additional, Colpani, Maria, additional, Gabbani, Tommaso, additional, Marsico, Maria, additional, Zappimbulso, Marianna, additional, Petruzzi, Josè, additional, Calvaruso, Vincenza, additional, Parrella, Giovanni, additional, Caporaso, Nicola, additional, Auriemma, Francesco, additional, Guarino, Maria, additional, Pugliese, Fabio, additional, Tortora, Annalisa, additional, Leo, Pietro, additional, Angelico, Mario, additional, De Leonardis, Francesco, additional, Pecchioli, Alessandra, additional, Rossi, Piera, additional, Raimondo, Giovanni, additional, Cacciola, Irene, additional, Elia, Gianfranco, additional, Negri, Elisa, additional, Dallio, Marcello, additional, Loguercio, Carmelina, additional, Federico, Alessandro, additional, Conte, Dario, additional, Massironi, Sara, additional, Natascia Celli, Giorgio Ballardini, additional, Rendina, Maria, additional, Bringiotti, Roberto, additional, Castellaneta, Nicola Maurizio, additional, Salerno, Francesco, additional, Boccia, Sergio, additional, Guarisco, Riccardo, additional, Galioto, Alessandra, additional, Cavallin, Marta, additional, and Andrealli, Alida, additional

Published
2021
Full Text
View/download PDF

34. The role of small intestinal bacterial overgrowth in Parkinsonʼs disease

Author

Fasano, Alfonso, Bove, Francesco, Gabrielli, Maurizio, Petracca, Martina, Zocco, Maria Assunta, Ragazzoni, Enzo, Barbaro, Federico, Piano, Carla, Fortuna, Serena, Tortora, Annalisa, Giacopo, Raffaella Di, Campanale, Mariachiara, Gigante, Giovanni, Lauritano, Ernesto Cristiano, Navarra, Pierluigi, Marconi, Stefano, Gasbarrini, Antonio, and Bentivoglio, Anna Rita

Published
2013
Full Text
View/download PDF

36. Impact of portal vein thrombosis on hepatocellular carcinoma treatment outcome. the hepatocat group experience: 558

Author

Ponziani, Francesca Romana, Zocco, Maria Assunta, Garcovich, Matteo, Cesario, Valentina, DʼAversa, Francesca, Di Rienzo, Teresa A., De Gaetano, Anna Maria, Rinninella, Emanuele, Roccarina, Davide, Campanale, Mariachiara, Barbaro, Federico, Tortora, Annalisa, Caracciolo, Gianluigi, Gigante, Giovanni, Ianiro, Gianluca, Siciliano, Massimo, Annicchiarico, Brigida E., Milani, Alessandro, Zaccaria, Raffaella, Sarno, Gerardo, Gasbarrini, Giovanni, Agnes, Salvatore, Avolio, Alfonso W., Grieco, Antonio, Nuzzo, Gennaro, Giuliante, Felice, Pompili, Maurizio, Rapaccini, Gian Ludovico, and Gasbarrini, Antonio

Published
2012

39. Long-term albumin administration is not futile in patients with cirrhosis and uncomplicated ascites not normalizing serum albumin concentration with treatment

Author

Tufoni, Manuel, primary, Caraceni, Paolo, additional, Zaccherini, Giacomo, additional, Riggio, Oliviero, additional, Angeli, Paolo, additional, Alessandria, Carlo, additional, Neri, Sergio, additional, Foschi, Francesco Giuseppe, additional, Levantesi, Fabio, additional, Airoldi, Aldo, additional, Simone, Loredana, additional, Svegiati-Baroni, Gianluca, additional, Fagiuoli, Stefano, additional, Laffi, Giacomo, additional, Cozzolongo, Raffaele, additional, Di Marco, Vito, additional, Sangiovanni, Vincenzo, additional, Morisco, Filomena, additional, Toniutto, Pierluigi, additional, Tortora, Annalisa, additional, De Marco, Rosanna, additional, Nardelli, Silvia, additional, Piano, Salvatore, additional, Elia, Chiara, additional, Roncadori, Andrea, additional, Baldassarre, Maurizio, additional, and Bernardi, Mauro, additional

Published
2020
Full Text
View/download PDF

40. Missed linkage to care for patients with chronic hepatitis C virus infection in a tertiary care center: results of the telepass project

Author

Ponziani, Francesca, primary, Santopaolo, Francesco, additional, Siciliano, Massimo, additional, De Belvis, Antonio, additional, Tortora, Annalisa, additional, Mora, Vincenzina, additional, Fanali, Caterina, additional, Morsella, Alisha, additional, Balducci, Fulvio, additional, Vetrugno, Giuseppe, additional, D’Alfonso, Maria Elena, additional, Cambieri, Andrea, additional, Cauda, Roberto, additional, Bellantone, Rocco, additional, Sanguinetti, Maurizio, additional, Pompili, Maurizio, additional, and Gasbarrini, Antonio, additional

Published
2020
Full Text
View/download PDF

41. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial

Author

Caraceni, Paolo, Riggio, Oliviero, Angeli, Paolo, Alessandria, Carlo, Neri, Sergio, Foschi, Francesco G, Levantesi, Fabio, Airoldi, Aldo, Boccia, Sergio, Svegliati-Baroni, Gianluca, Fagiuoli, Stefano, Romanelli, Roberto G, Cozzolongo, Raffaele, Di Marco, Vito, Sangiovanni, Vincenzo, Morisco, Filomena, Toniutto, Pierluigi, Tortora, Annalisa, De Marco, Rosanna, Angelico, Mario, Cacciola, Irene, Elia, Gianfranco, Federico, Alessandro, Massironi, Sara, Guarisco, Riccardo, Galioto, Alessandra, Ballardini, Giorgio, Rendina, Maria, Nardelli, Silvia, Piano, Salvatore, Elia, Chiara, Prestianni, Loredana, Cappa, Federica Mirici, Cesarini, Lucia, Simone, Loredana, Pasquale, Chiara, Cavallin, Marta, Andrealli, Alida, Fidone, Federica, Ruggeri, Matteo, Roncadori, Andrea, Baldassarre, Maurizio, Tufoni, Manuel, Zaccherini, Giacomo, Bernardi, Mauro, Domenicali, Marco, Giannone, Ferdinando A, Merli, Manuela, Gioia, Stefania, Fasolato, Silvano, Sticca, Antonietta, Campion, Daniela, Risso, Alessandro, Saracco, Giorgio M, Maiorca, Daniela, Rizzotto, Agostino, Lanzi, Arianna, Neri, Elga, Visani, Anna, Mastroianni, Antonio, Alberti, Alberto B, Mazzarelli, Chiara, Vangeli, Marcello, Marzioni, Marco, Capretti, Francesca, Kostandini, Alba, Magini, Giulia, Colpani, Maria, Laffi, Giacomo, Gabbani, Tommaso, Marsico, Maria, Zappimbulso, Marianna, Petruzzi, Josè, Calvaruso, Vincenza, Parrella, Giovanni, Caporaso, Nicola, Auriemma, Francesco, Guarino, Maria, Pugliese, Fabio, Gasbarrini, Antonio, Leo, Pietro, De Leonardis, Francesco, Pecchioli, Alessandra, Rossi, Piera, Raimondo, Giovanni, Negri, Elisa, Dallio, Marcello, Loguercio, Carmelina, Conte, Dario, Celli, Natascia, Bringiotti, Roberto, Castellaneta, Nicola M, Salerno, Francesco, ANSWER Study Investigators, Caraceni, Paolo, Riggio, Oliviero, Angeli, Paolo, Alessandria, Carlo, Neri, Sergio, Foschi, Francesco G, Levantesi, Fabio, Airoldi, Aldo, Boccia, Sergio, Svegliati-Baroni, Gianluca, Fagiuoli, Stefano, Romanelli, Roberto G, Cozzolongo, Raffaele, Di Marco, Vito, Sangiovanni, Vincenzo, Morisco, Filomena, Toniutto, Pierluigi, Tortora, Annalisa, De Marco, Rosanna, Angelico, Mario, Cacciola, Irene, Elia, Gianfranco, Federico, Alessandro, Massironi, Sara, Guarisco, Riccardo, Galioto, Alessandra, Ballardini, Giorgio, Rendina, Maria, Nardelli, Silvia, Piano, Salvatore, Elia, Chiara, Prestianni, Loredana, Cappa, Federica Mirici, Cesarini, Lucia, Simone, Loredana, Pasquale, Chiara, Cavallin, Marta, Andrealli, Alida, Fidone, Federica, Ruggeri, Matteo, Roncadori, Andrea, Baldassarre, Maurizio, Tufoni, Manuel, Zaccherini, Giacomo, Bernardi, Mauro, Domenicali, Marco, Giannone, Ferdinando A, Merli, Manuela, Gioia, Stefania, Fasolato, Silvano, Sticca, Antonietta, Campion, Daniela, Risso, Alessandro, Saracco, Giorgio M, Maiorca, Daniela, Rizzotto, Agostino, Lanzi, Arianna, Neri, Elga, Visani, Anna, Mastroianni, Antonio, Alberti, Alberto B, Mazzarelli, Chiara, Vangeli, Marcello, Marzioni, Marco, Capretti, Francesca, Kostandini, Alba, Magini, Giulia, Colpani, Maria, Laffi, Giacomo, Gabbani, Tommaso, Marsico, Maria, Zappimbulso, Marianna, Petruzzi, Josè, Calvaruso, Vincenza, Parrella, Giovanni, Caporaso, Nicola, Auriemma, Francesco, Guarino, Maria, Pugliese, Fabio, Gasbarrini, Antonio, Leo, Pietro, De Leonardis, Francesco, Pecchioli, Alessandra, Rossi, Piera, Raimondo, Giovanni, Negri, Elisa, Dallio, Marcello, Loguercio, Carmelina, Conte, Dario, Celli, Natascia, Bringiotti, Roberto, Castellaneta, Nicola M, Salerno, Francesco, Caraceni P1, Riggio O2, Angeli P3, Alessandria C4, Neri S5, Foschi FG6, Levantesi F7, Airoldi A8, Boccia S9, Svegliati-Baroni G10, Fagiuoli S11, Romanelli RG12, Cozzolongo R13, Di Marco Vito, Sangiovanni V15, Morisco F16, Toniutto P17, Tortora A18, De Marco R19, Angelico M20, Cacciola I21, Elia G22, Federico A23, Massironi S24, Guarisco R25, Galioto A26, Ballardini G27, Rendina M28, Nardelli S2, Piano S3, Elia C4, Prestianni L5, Cappa FM6, Cesarini L8, Simone L9, Pasquale C2, Cavallin M3, Andrealli A4, Fidone F5, Ruggeri M29, Roncadori A30, Baldassarre M1, Tufoni M1, Zaccherini G1, Bernardi M31, Domenicali M, Giannone FA, Merli M, Gioia S, Fasolato S, Sticca A, Campion D, Risso A, Saracco GM, Maiorca D, Rizzotto A, Lanzi A, Neri E, Visani A, Mastroianni A, Alberti AB, Mazzarelli C, Vangeli M, Marzioni M, Capretti F, Kostandini A, Magini G, Colpani M, Laffi G, Gabbani T, Marsico M, Zappimbulso M, Petruzzi J, Calvaruso Vincenza, Parrella G, Caporaso N, Auriemma F, Guarino M, Pugliese F, Gasbarrini A, Leo P, De Leonardis F, Pecchioli A, Rossi P, Raimondo G, Negri E, Dallio M, Loguercio C, Conte D, Celli N, Bringiotti R, Castellaneta NM, Salerno F., Caraceni P, Riggio O, Angeli P, Alessandria C, Neri S, Foschi FG, Levantesi F, Airoldi A, Boccia S, Svegliati-Baroni G, Fagiuoli S, Romanelli RG, Cozzolongo R, Di Marco V, Sangiovanni V, Morisco F, Toniutto P, Tortora A, De Marco R, Angelico M, Cacciola I, Elia G, Federico A, Massironi S, Guarisco R, Galioto A, Ballardini G, Rendina M, Nardelli S, Piano S, Elia C, Prestianni L, Cappa FM, Cesarini L, Simone L, Pasquale C, Cavallin M, Andrealli A, Fidone F, Ruggeri M, Roncadori A, Baldassarre M, Tufoni M, Zaccherini G, Bernardi M, Domenicali M, Giannone FA, Merli M, Gioia S, Fasolato S, Sticca A, Campion D, Risso A, Saracco GM, Maiorca D, Rizzotto A, Lanzi A, Neri E, Visani A, Mastroianni A, Alberti AB, Mazzarelli C, Vangeli M, Marzioni M, Capretti F, Kostandini A, Magini G, Colpani M, Laffi G, Gabbani T, Marsico M, Zappimbulso M, Petruzzi J, Calvaruso V, Parrella G, Caporaso N, Auriemma F, Guarino M, Pugliese F, Gasbarrini A, Leo P, De Leonardis F, Pecchioli A, Rossi P, Raimondo G, Negri E, Dallio M, Loguercio C, Conte D, Celli N, Bringiotti R, Castellaneta NM, Salerno F., Caraceni, P, Riggio, O, Angeli, P, Alessandria, C, Neri, S, Foschi, F, Levantesi, F, Airoldi, A, Boccia, S, Svegliati-Baroni, G, Fagiuoli, S, Romanelli, R, Cozzolongo, R, Di Marco, V, Sangiovanni, V, Morisco, F, Toniutto, P, Tortora, A, De Marco, R, Angelico, M, Cacciola, I, Elia, G, Federico, A, Massironi, S, Guarisco, R, Galioto, A, Ballardini, G, Rendina, M, Nardelli, S, Piano, S, Elia, C, Prestianni, L, Cappa, F, Cesarini, L, Simone, L, Pasquale, C, Cavallin, M, Andrealli, A, Fidone, F, Ruggeri, M, Roncadori, A, Baldassarre, M, Tufoni, M, Zaccherini, G, Bernardi, M, Domenicali, M, Giannone, F, Merli, M, Gioia, S, Fasolato, S, Sticca, A, Campion, D, Risso, A, Saracco, G, Maiorca, D, Rizzotto, A, Lanzi, A, Neri, E, Visani, A, Mastroianni, A, Alberti, A, Mazzarelli, C, Vangeli, M, Marzioni, M, Capretti, F, Kostandini, A, Magini, G, Colpani, M, Laffi, G, Gabbani, T, Marsico, M, Zappimbulso, M, Petruzzi, J, Calvaruso, V, Parrella, G, Caporaso, N, Auriemma, F, Guarino, M, Pugliese, F, Gasbarrini, A, Leo, P, De Leonardis, F, Pecchioli, A, Rossi, P, Raimondo, G, Negri, E, Dallio, M, Loguercio, C, Conte, D, Celli, N, Bringiotti, R, Castellaneta, N, and Salerno, F

Subjects
Liver Cirrhosis, Male, Time Factors, Cirrhosis, Kaplan-Meier Estimate, law.invention, ascites, 0302 clinical medicine, Hepatorenal syndrome, Randomized controlled trial, Furosemide, law, Ascites, Clinical endpoint, Paracentesis, Diuretics, albumin, decompensated cirrhosi, Mineralocorticoid Receptor Antagonists, Settore MED/12 - Gastroenterologia, Medicine (all), Hazard ratio, General Medicine, Middle Aged, Survival Rate, 030220 oncology & carcinogenesis, Drug Therapy, Combination, Female, 030211 gastroenterology & hepatology, Quality-Adjusted Life Years, medicine.symptom, Hyponatremia, medicine.medical_specialty, 03 medical and health sciences, Albumins, Internal medicine, medicine, Humans, Survival rate, albumin, Aged, business.industry, cirrhosis, medicine.disease, Clinical trial, albumin, cirrhosis, ascites, liver decompensation, Quality of Life, Hyperkalemia, business, Esophagus Varices, Portal Hypertension, Varicosis
Abstract

Background Evidence is scarce on the efficacy of long-term human albumin (HA) administration in patients with decompensated cirrhosis. The human Albumin for the treatmeNt of aScites in patients With hEpatic ciRrhosis (ANSWER) study was designed to clarify this issue. Methods We did an investigator-initiated multicentre randomised, parallel, open-label, pragmatic trial in 33 academic and non-academic Italian hospitals. We randomly assigned patients with cirrhosis and uncomplicated ascites who were treated with anti-aldosteronic drugs (≥200 mg/day) and furosemide (≥25 mg/day) to receive either standard medical treatment (SMT) or SMT plus HA (40 g twice weekly for 2 weeks, and then 40 g weekly) for up to 18 months. The primary endpoint was 18-month mortality, evaluated as difference of events and analysis of survival time in patients included in the modified intention-to-treat and per-protocol populations. This study is registered with EudraCT, number 2008–000625–19, and ClinicalTrials.gov, number NCT01288794. Findings From April 2, 2011, to May 27, 2015, 440 patients were randomly assigned and 431 were included in the modified intention-to-treat analysis. 38 of 218 patients died in the SMT plus HA group and 46 of 213 in the SMT group. Overall 18-month survival was significantly higher in the SMT plus HA than in the SMT group (Kaplan-Meier estimates 77% vs 66%; p=0·028), resulting in a 38% reduction in the mortality hazard ratio (0·62 [95% CI 0·40–0·95]). 46 (22%) patients in the SMT group and 49 (22%) in the SMT plus HA group had grade 3–4 non-liver related adverse events. Interpretation In this trial, long-term HA administration prolongs overall survival and might act as a disease modifying treatment in patients with decompensated cirrhosis. Funding Italian Medicine Agency. Copyright © 2018 Elsevier Ltd. All rights reserved.

Published
2018

42. SAT535 - Correction and prevention of hyponatremia in patients with cirrhosis and ascites-post hoc analysis of the ANSWER study database

Author

Zaccherini, Giacomo, Baldassarre, Maurizio, Tufoni, Manuel, Riggio, Oliviero, Angeli, Paolo, Alessandria, Carlo, Neri, Sergio, Foschi, Francesco Giuseppe, Levantesi, Fabio, Airoldi, Aldo, Simone, Loredana, Svegiati-Baroni, Gianluca, Fagiuoli, Stefano, Laffi, Giacomo, Cozzolongo, Raffaele, Di Marco, Vito, Sangiovanni, Vincenzo, Morisco, Filomena, Toniutto, Pierluigi, Tortora, Annalisa, De Marco, Rosanna, Nardelli, Silvia, Piano, Salvatore, Elia, Chiara, Bernardi, Mauro, and Caraceni, Paolo

Published
2022
Full Text
View/download PDF

43. COMMON CLINICAL COMORBIDITIES IN AN ITALIAN NAFLD COHORT

Author

Miele, Luca, Liguori, Antonio, Marrone, G, Ponziani, Francesca Romana, Spiniello, L, Tortora, Annalisa, Ainora, Maria Elena, Rinninella, Emanuele, De Matthaeis, Nicoletta, Pizzolante, Fabrizio, Khadim, C, Biolato, Marco, Zocco, Maria Assunta, Riccardi, Laura, Mele, Maria Cristina, Siciliano, M, Addolorato, Giovanni, Pompili, Maurizio, Rapaccini, Gian Ludovico, Gasbarrini, Antonio, and Grieco, A

Subjects
N/A, Settore MED/12 - GASTROENTEROLOGIA
Published
2018

44. PS-083-Serum albumin concentration as guide for long-term albumin treatment in patients with cirrhosis and uncomplicated ascites: Lessons from the ANSWER study

Author

Caraceni, Paolo, primary, Riggio, Oliviero, additional, Angeli, Paolo, additional, Alessandria, Carlo, additional, Neri, Sergio, additional, Foschi, Francesco Giuseppe, additional, Levantesi, Fabio, additional, Airoldi, Aldo, additional, Simone, Loredana, additional, Svegiati-Baroni, Gianluca, additional, Fagiuoli, Stefano, additional, Romanelli, Roberto Giulio, additional, Cozzolongo, Raffaele, additional, Marco, Vito Di, additional, Sangiovanni, Vincenzo, additional, Morisco, Filomena, additional, Toniutto, Pierluigi, additional, Tortora, Annalisa, additional, Marco, Rosanna De, additional, Nardelli, Silvia, additional, Piano, Salvatore, additional, Elia, Chiara, additional, Roncadori, Andrea, additional, Tufoni, Manuel, additional, Zaccherini, Giacomo, additional, and Bernardi, Mauro, additional

Published
2019
Full Text
View/download PDF

45. Treatment of early stage chronic hepatitis C virus infection

Author

Ponziani, Francesca Romana, Miele, Luca, Tortora, Annalisa, Furnari, Manuele, Bodini, Giorgia, Pompili, Maurizio, Gasbarrini, Antonio, Giannini, Edoardo Giovanni, Ponziani, Francesca Romana (ORCID:0000-0002-5924-6238), Miele, Luca (ORCID:0000-0003-3464-0068), Pompili, Maurizio (ORCID:0000-0001-6699-7980), Gasbarrini, Antonio (ORCID:0000-0002-7278-4823), Ponziani, Francesca Romana, Miele, Luca, Tortora, Annalisa, Furnari, Manuele, Bodini, Giorgia, Pompili, Maurizio, Gasbarrini, Antonio, Giannini, Edoardo Giovanni, Ponziani, Francesca Romana (ORCID:0000-0002-5924-6238), Miele, Luca (ORCID:0000-0003-3464-0068), Pompili, Maurizio (ORCID:0000-0001-6699-7980), and Gasbarrini, Antonio (ORCID:0000-0002-7278-4823)

Abstract

Introduction: Treatment of Hepatitis C Virus (HCV) with direct acting antivirals (DAAs) is able to achieve the cure of infection in almost the totality of patients, independently of the characteristics of the individual and the virus, using short treatment schedules, and without the need of ribavirin. The high cost of DAAs is the main limiting factor for universal treatment of HCV. However, there is a strong evidence that treatment of infection at the early stage of disease may be the most rewarding approach. Areas covered: This review evaluates the aspects underlying the benefit of treating chronic HCV infection at the early stage of disease. It outlines the considerations that have to be taken into account when planning treatment in patients with HCV and minimal liver disease, assessing the positive reflex of viral eradication on several HCV-associated extra-hepatic conditions such as the risk of lymphoma, insulin-resistance and glycaemic control, and renal function. Lastly, it also covers the improvement of patients’ quality of life and the pharmaco-economic aspects associated with early treatment. Expert commentary: Treatment of patients with HCV and minimal liver disease is associated with a beneficial, pleiotropic effect of viral eradication that goes beyond the simplistic consideration of the improvement in liver disease-related outcomes.

Published
2018

46. The use of single balloon enteroscopy in Crohn’s disease and its impact on clinical outcome

Author

Holleran, Grainne, Valerii, Giorgio, Tortora, Annalisa, Scaldaferri, Franco, Conti, Silvia, Amato, Arianna, Gasbarrini, Antonio, Costamagna, Guido, Riccioni, Maria Elena, Scaldaferri, Franco (ORCID:0000-0001-8334-7541), Gasbarrini, Antonio (ORCID:0000-0002-7278-4823), Costamagna, Guido (ORCID:0000-0002-8100-2731), Riccioni, Maria Elena (ORCID:0000-0002-9239-4312), Holleran, Grainne, Valerii, Giorgio, Tortora, Annalisa, Scaldaferri, Franco, Conti, Silvia, Amato, Arianna, Gasbarrini, Antonio, Costamagna, Guido, Riccioni, Maria Elena, Scaldaferri, Franco (ORCID:0000-0001-8334-7541), Gasbarrini, Antonio (ORCID:0000-0002-7278-4823), Costamagna, Guido (ORCID:0000-0002-8100-2731), and Riccioni, Maria Elena (ORCID:0000-0002-9239-4312)

Abstract

Objectives: Single balloon enteroscopy (SBE) is an effective and safe modality for the diagnosis and therapeutic intervention of small bowel disorders. Its use in patients with Crohn’s disease (CD) and particularly its effect on management changes in CD have not yet been determined. Materials and methods: We performed a retrospective review of the endoscopic and clinical data available on a cohort of patients with small bowel CD who had undergone SBE to determine the diagnostic and therapeutic yield of the procedure and the initial and longer-term impact it had on clinical management. Results: About 52 patients have undergone SBE in our unit for the investigation of known (n = 39) or suspected (n = 13) small bowel CD with a diagnostic yield of 77% and 39%, respectively. SBE had an immediate clinical impact in 69% (n = 33) of patients, including dilatation of a stricture in 27% (n = 13), initiation or adjustment of dose of medications in 48% (n = 23), referral for surgical resection in 6% (n = 3). Moreover, the procedure permitted determining a new diagnosis of CD in 8% of the patients (n = 4), and excluding it in 8% (n = 4). Longer term follow-up was available in 34 patients (65%) which showed a significant difference in mean HBI score from 6.6 before the procedure to 4.2 after it (p <.0001). Conclusions: SBE has a high diagnostic and therapeutic yield in CD and significantly impacts disease management. Careful patient selection is a key factor in optimizing its use in CD.

Published
2018

47. Regorafenib: a promising treatment for hepatocellular carcinoma

Author

Cerrito, Lucia, Ponziani, Francesca Romana, Garcovich, Matteo, Tortora, Annalisa, Annicchiarico, Brigida Eleonora, Pompili, Maurizio, Siciliano, Massimo, Gasbarrini, Antonio, Ponziani, Francesca R. (ORCID:0000-0002-5924-6238), Annicchiarico, Brigida E., Pompili, Maurizio (ORCID:0000-0001-6699-7980), Gasbarrini, Antonio (ORCID:0000-0002-7278-4823), Cerrito, Lucia, Ponziani, Francesca Romana, Garcovich, Matteo, Tortora, Annalisa, Annicchiarico, Brigida Eleonora, Pompili, Maurizio, Siciliano, Massimo, Gasbarrini, Antonio, Ponziani, Francesca R. (ORCID:0000-0002-5924-6238), Annicchiarico, Brigida E., Pompili, Maurizio (ORCID:0000-0001-6699-7980), and Gasbarrini, Antonio (ORCID:0000-0002-7278-4823)

Abstract

Introduction: Hepatocellular carcinoma (HCC) is one of the most frequent malignant tumors with 854,000 new cases per year and represents the second most frequent cause of cancer-death. Despite surveillance, the number of patients that are diagnosed at a stage in which they are eligible for curative treatments ranges from 30% to 60%. Advanced HCC (BCLC-C) is characterized by a median survival of 6 months. Sorafenib, the first systemic drug proven to be effective in prolonging survival of unresectable HCC, was approved by the FDA in 2007 but no second-line treatment was available for a decade for patients progressing on sorafenib. Finally, in 2016, the RESORCE trial demonstrated regorafenib as an effective second-line treatment. Areas covered: In this manuscript, the authors review the principal preclinical and clinical trials on regorafenib used in the treatment of unresectable HCC patients progressing on sorafenib and highlight both the advantages and the limitations of this drug. Expert opinion: Regorafenib is the only second-line treatment available for patients progressing on sorafenib. Despite its promising clinical application, many doubts still remain, necessitating further investigation to explore the tolerability of this drug in Child-Pugh B and sorafenib-intolerant patients, while its scarce cost-effectiveness must also be improved.

Published
2018

50. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial

Author

Caraceni, Paolo, primary, Riggio, Oliviero, additional, Angeli, Paolo, additional, Alessandria, Carlo, additional, Neri, Sergio, additional, Foschi, Francesco G, additional, Levantesi, Fabio, additional, Airoldi, Aldo, additional, Boccia, Sergio, additional, Svegliati-Baroni, Gianluca, additional, Fagiuoli, Stefano, additional, Romanelli, Roberto G, additional, Cozzolongo, Raffaele, additional, Di Marco, Vito, additional, Sangiovanni, Vincenzo, additional, Morisco, Filomena, additional, Toniutto, Pierluigi, additional, Tortora, Annalisa, additional, De Marco, Rosanna, additional, Angelico, Mario, additional, Cacciola, Irene, additional, Elia, Gianfranco, additional, Federico, Alessandro, additional, Massironi, Sara, additional, Guarisco, Riccardo, additional, Galioto, Alessandra, additional, Ballardini, Giorgio, additional, Rendina, Maria, additional, Nardelli, Silvia, additional, Piano, Salvatore, additional, Elia, Chiara, additional, Prestianni, Loredana, additional, Cappa, Federica Mirici, additional, Cesarini, Lucia, additional, Simone, Loredana, additional, Pasquale, Chiara, additional, Cavallin, Marta, additional, Andrealli, Alida, additional, Fidone, Federica, additional, Ruggeri, Matteo, additional, Roncadori, Andrea, additional, Baldassarre, Maurizio, additional, Tufoni, Manuel, additional, Zaccherini, Giacomo, additional, Bernardi, Mauro, additional, Domenicali, Marco, additional, Giannone, Ferdinando A, additional, Merli, Manuela, additional, Gioia, Stefania, additional, Fasolato, Silvano, additional, Sticca, Antonietta, additional, Campion, Daniela, additional, Risso, Alessandro, additional, Saracco, Giorgio M, additional, Maiorca, Daniela, additional, Rizzotto, Agostino, additional, Lanzi, Arianna, additional, Neri, Elga, additional, Visani, Anna, additional, Mastroianni, Antonio, additional, Alberti, Alberto B, additional, Mazzarelli, Chiara, additional, Vangeli, Marcello, additional, Marzioni, Marco, additional, Capretti, Francesca, additional, Kostandini, Alba, additional, Magini, Giulia, additional, Colpani, Maria, additional, Laffi, Giacomo, additional, Gabbani, Tommaso, additional, Marsico, Maria, additional, Zappimbulso, Marianna, additional, Petruzzi, Josè, additional, Calvaruso, Vincenza, additional, Parrella, Giovanni, additional, Caporaso, Nicola, additional, Auriemma, Francesco, additional, Guarino, Maria, additional, Pugliese, Fabio, additional, Gasbarrini, Antonio, additional, Leo, Pietro, additional, De Leonardis, Francesco, additional, Pecchioli, Alessandra, additional, Rossi, Piera, additional, Raimondo, Giovanni, additional, Negri, Elisa, additional, Dallio, Marcello, additional, Loguercio, Carmelina, additional, Conte, Dario, additional, Celli, Natascia, additional, Bringiotti, Roberto, additional, Castellaneta, Nicola M, additional, and Salerno, Francesco, additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results